(Q43544031)

24 November 2017

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose (English)

1 reference

24 November 2017

1 reference

3

1 reference

24 November 2017

4

1 reference

24 November 2017

Vilsbøll T

1

1 reference

PubMed ID

11251679

24 November 2017

Krarup T

series ordinal

2

1 reference

PubMed ID

11251679

24 November 2017

language of work or name

1 reference

1 February 2001

1 reference

24 November 2017

1 reference

24 November 2017

18

1 reference

24 November 2017

2

1 reference

24 November 2017

144-149

1 reference

Glucagon-like peptide-1 7-36: a physiological incretin in man.

24 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Radioimmunological determination of human C-peptide in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Characterization of seven C-peptide antisera

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00424.X

10.1046/J.1464-5491.2001.00424.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference

PubMed ID

11251679